Diabetes remains one of the world's fastest-growing chronic health conditions, affecting hundreds of millions of people globally. While insulin has long been a cornerstone of diabetes treatment, recent advancements in non-insulin therapies are transforming how patients manage blood glucose levels and reduce long-term complications. These therapies offer greater convenience, improved patient compliance, and additional health benefits, making them increasingly attractive to both healthcare providers and patients.
According to industry estimates, the global Non-insulin
Therapies for Diabetes Market was valued at US$ 31.8 billion in 2023
and is expected to reach US$ 58.6 billion by 2034, expanding at a CAGR of 5.8%
from 2024 to 2034. Rising diabetes prevalence, growing awareness of disease
management, and continuous pharmaceutical innovation are expected to fuel
market growth throughout the forecast period.
The Growing Global Diabetes Challenge
Diabetes has become a major public health concern worldwide.
Sedentary lifestyles, unhealthy dietary habits, obesity, aging populations, and
genetic predisposition have contributed to a steady increase in the number of
individuals diagnosed with both type 1 and type 2 diabetes.
Among these, type 2 diabetes accounts for the vast majority
of cases. Many patients initially manage their condition through lifestyle
changes and oral medications before progressing to more advanced treatments. As
healthcare systems seek effective ways to manage the growing diabetes burden,
non-insulin therapies are gaining significant attention due to their ability to
improve glycemic control while minimizing treatment complexity.
The increasing focus on preventive healthcare and early
intervention is further encouraging the adoption of innovative diabetes
therapies.
Why Non-insulin Therapies Are Gaining Popularity
One of the primary advantages of non-insulin therapies is
their ability to help patients manage blood sugar levels without requiring
insulin injections. This can significantly improve treatment adherence,
especially among newly diagnosed patients and those seeking less invasive
treatment options.
Many modern non-insulin therapies offer additional benefits
beyond glucose control. Certain drug classes have demonstrated positive effects
on weight management, cardiovascular health, and kidney protection—important
considerations given the close relationship between diabetes and other chronic
conditions.
These advantages are encouraging physicians to increasingly
prescribe non-insulin treatments as part of comprehensive diabetes management
strategies.
GLP-1 Receptor Agonists Driving Market Momentum
Among the most significant developments in diabetes care has
been the rise of GLP-1 receptor agonists. These therapies help regulate blood
sugar levels by enhancing insulin secretion, slowing gastric emptying, and
reducing appetite.
The growing popularity of GLP-1-based treatments has
significantly reshaped the competitive landscape of the diabetes market. Their
effectiveness in both blood glucose management and weight reduction has
generated strong demand among patients and healthcare providers alike.
Pharmaceutical companies continue to invest heavily in
developing new formulations, including oral versions that offer greater
convenience compared to injectable therapies.
The success of these treatments is expected to remain a
major growth driver for the non-insulin therapies market over the coming
decade.
Increasing Research and Clinical Development Activities
The competitive environment within the diabetes treatment
sector is characterized by extensive research and development efforts. Leading
pharmaceutical companies are actively conducting clinical trials aimed at
improving efficacy, safety, and patient convenience.
Researchers are exploring new mechanisms of action that
target multiple metabolic pathways simultaneously. These innovations have the
potential to deliver better outcomes while addressing unmet needs among
patients who do not achieve adequate control through existing therapies.
Advancements in precision medicine and personalized
healthcare are also influencing diabetes treatment development. Future
therapies may be increasingly tailored to individual patient characteristics,
helping optimize treatment effectiveness and reduce adverse effects.
Pharmaceutical Companies Strengthening Their Market
Positions
The non-insulin therapies market features strong competition
among global pharmaceutical manufacturers seeking to expand their presence
within the rapidly growing diabetes sector.
Key companies operating in the market include GSK plc, Eli
Lilly and Company, Sumitomo Pharma, Intarcia Therapeutics, Servier
Laboratories, Pfizer Inc., Merck & Co., Inc., Dong-A Pharmaceutical Co.,
Ltd., Luye Pharma Group, and Eurofarma Laboratories SA.
These organizations are investing heavily in clinical
research, strategic collaborations, regulatory approvals, and product
development initiatives to strengthen their competitive positions.
Many companies are also pursuing partnerships with
healthcare providers and research institutions to accelerate innovation and
improve access to advanced diabetes treatments.
Regulatory Support Accelerating Innovation
Regulatory agencies worldwide are increasingly recognizing
the importance of innovative diabetes therapies that can improve patient
outcomes and reduce healthcare burdens.
Favorable regulatory pathways are helping pharmaceutical
companies bring new products to market more efficiently while ensuring safety
and effectiveness standards are maintained.
The growing number of approvals for advanced non-insulin
therapies demonstrates the industry's commitment to addressing the evolving
needs of diabetes patients globally.
As healthcare systems emphasize disease prevention and
chronic disease management, regulatory support is expected to remain a key
factor driving market expansion.
Recent Industry Developments
Recent developments highlight the strong innovation momentum
within the non-insulin therapies for diabetes market.
In June 2023, Pfizer provided an important update regarding
its GLP-1 receptor agonist clinical development program. The company announced
continued advancement of danuglipron, its oral GLP-1 candidate, toward
late-stage development for adults living with obesity and type 2 diabetes. The
progress reflects growing industry confidence in oral GLP-1 therapies as a
future growth segment.
Meanwhile, GSK continues to maintain a notable presence in
the diabetes treatment market through its FDA-approved once-weekly therapy
Tanzeum. The product has contributed significantly to the company's position
within the broader diabetes therapeutics landscape and highlights the long-term
value of innovative treatment solutions.
Future Outlook
The future of the Non-insulin Therapies for Diabetes Market
appears highly promising. Rising diabetes prevalence, increasing healthcare
expenditures, and growing patient demand for convenient treatment options are
expected to support sustained market growth through 2034.
Emerging therapies that offer improved efficacy, fewer side
effects, and additional cardiovascular or metabolic benefits will likely play
an increasingly important role in diabetes management. The continued expansion
of oral treatment options and next-generation GLP-1 therapies could further
transform the treatment landscape.
As pharmaceutical innovation accelerates and healthcare
providers prioritize patient-centered care, non-insulin therapies are expected
to become an even more critical component of diabetes treatment strategies
worldwide. With the market projected to reach US$ 58.6 billion by 2034,
stakeholders across the healthcare ecosystem have significant opportunities to
participate in one of the most dynamic segments of modern medicine.
About Us Transparency Market Research
Transparency Market Research, a global market research company registered at
Wilmington, Delaware, United States, provides custom research and consulting
services. The firm scrutinizes factors shaping the dynamics of demand in
various markets. The insights and perspectives on the markets evaluate
opportunities in various segments. The opportunities in the segments based on
source, application, demographics, sales channel, and end-use are analysed,
which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insights for thousands of decision-makers, made possible by
experienced teams of Analysts, Researchers, and Consultants. The proprietary
data sources and various tools & techniques we use always reflect the
latest trends and information. With a broad research and analysis capability, Transparency
Market Research employs rigorous primary and secondary research techniques in
all of its business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
No comments:
Post a Comment